SAULO BRITO SILVA
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
- Patterns of post-operative radiotherapy in breast cancer patients after neoadjuvant chemotherapy(2017) LOPES, K. M.; FREITAS, T. B. De; CARVALHO, H. A.; PEREIRA, A. A.; SILVA, S. B.; STUART, S. R.; MANO, M. S.; FILASSI, J. R.; MARTA, G. N.
- Metaplastic breast cancer: A single-institution experience.(2016) SILVA, Aumilto Augusto; LINCK, Rudinei Diogo Marques; LIMA, Julianne Maria da Silva; MATUTINO, Adriana Reis Brandao; SILVA, Saulo Brito; VICENTINI, Maria Fernanda; FELIZOLA, Marcelo; GAGLIATO, Debora De Melo; HOFF, Paulo Marcelo; MANO, Max S.
- Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy(2019) LIMA, Kennya Medeiros L. de B.; PEREIRA, Allan A. Lima; FREITAS, Thiago B. de; SILVA, Saulo Brito; CARVALHO, Heloisa de Andrade; MANO, Max S.; MARTA, Gustavo NaderBackground/Aim: Post-operative radiation therapy (PORT) is associated with improvement in loco-regional control and survival rates in early breast cancer. However, the evidence of benefit in patients after treatment with neoadjuvant chemotherapy (NAC) is poor. We aimed to assess the impact of the type of surgery in the PORT plan and the role of the PORT fields in clinical outcomes in breast cancer patients who had undergone NAC followed by surgery. Materials and methods: We performed a retrospective analysis of all non-metastatic breast cancer patients treated between 2008 and 2014 at our institution who had received NAC and PORT. Results: A total of 528 women were included of whom 396 were submitted to mastectomy or nipple-sparing/skin-sparing mastectomy. Most (92.8%) of the patients had locally advanced disease (clinical stage IIB to IIIC). All patients underwent irradiation for breast or chest wall. Most patients received PORT to the supraclavicular and axillary (levels II and III) nodes (87.1% and 86.4% for breast-conserving surgery and 95.1% and 93.8% for mastectomy and nipple-sparing/skin-sparing mastectomy, respectively). Irradiation of level I axillary and internal mammary nodes was uncommon. The disease-free survival and overall survival rates at 3 years were 72% and 85%, respectively. There were no statistically significant differences in clinical outcomes according to the use of nodal irradiation. Conclusions: After NAC, most patients received irradiation of the breast/chest wall and axillary and supraclavicular nodes. In this setting, PORT to breast/chest wall with or without regional nodal irradiation was safe and effective, with acceptable disease-free and overall survival rates reported in this high-risk population.
conferenceObject Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancer(2015) LIMA, J. M. Silva; MATUTINO, A.; SILVA, S. Brito; SILVA-JUNIOR, A. A.; BOAS, M. Vilas; STEPHAN, B. Oliveira; VAIRSBERG, V. Van; PEREIRA, A. A. Lima; BARROSO-SOUSA, R.; MANO, M. SennabookPart Urgências oncológicas(2016) TESTA, Laura; GIRARDI, Daniel da Motta; VIVEIROS, Pedro Antonio Hermida de; SILVA, Saulo Brito; SANTOS, Vanessa Montes- Impact of radiation therapy delay in patients underwent neoadjuvant chemotherapy and breast surgery(2017) SILVA, S.; PEREIRA, A.; KENNYA, M.; GUSTAVO, M.; MANO, M.
- Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer(2018) SILVA, Saulo Brito; PEREIRA, Allan Andresson Lima; MARTA, Gustavo Nader; LIMA, Kennya Medeiros Lopes de Barros; FREITAS, Thiago Brasileiro de; MATUTINO, Adriana Reis Brandao; SOUZA, Manoel Carlos Leonardi de Azevedo; AZEVEDO, Renata Gondim Meira Velame de; VIVEIROS, Pedro Antonio Hermida de; LIMA, Julianne Maria da Silva; FILASSI, Jose Roberto; CARVALHO, Heloisa de Andrade; PIATO, Jose Roberto Morales; MANO, Max S.Background: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown. Material and methods: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: < 8 weeks, 8-16 weeks and > 16 weeks. Results: A total of 581 patients were included; 74% had clinical stage III. Forty-three patients started PORT within 8 weeks, 354 between 8 and 16 weeks and 184 beyond 16 weeks from surgery. With a median follow-up of 32 months, initiation of PORT up to 8 weeks after surgery was associated with better disease-free survival (DFS) (< 8 weeks versus 8-16 weeks: HR 0.33; 95% CI 0.13-0.81; p = 0.02; < 8 weeks versus > 16 weeks: HR 0.38; 95% CI 0.15-0.96; p = 0.04) and better overall survival (OS) (< 8 weeks versus 8-16 weeks: HR 0.22; 95% CI 0.05-0.90; p = 0.036; < 8 weeks versus > 16 weeks: HR 0.28; 95% CI 0.07-1.15; p = 0.08). Conclusion: PORT started up to 8 weeks after surgery was associated with better DFS and OS in locally-advanced BC patients submitted to NAC. Our findings suggest that early initiation of PORT is critically important for these patients. However, the low numbers of patients and events in this study prevent us from drawing firm conclusions.
conferenceObject Neoadjuvant chemotherapy for elderly breast cancer patients(2015) MATUTINO, A. Reis Brandao; LIMA, J. M. Silva; SILVA, S. Brito; BOAS, M. Vilas; STEPHAN, B. Oliveira; VAIRSBERG, V. Van; FRAILE, N. Moreno Perez; BARROSO-SOUSA, R.; MANO, M. Senna